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Abstract
Factor XIII is a blood protransglutaminase that is distributed
in plasma and platelets. The extracellular and intracellular
zymogenic forms differ in that the plasma zymogen contains A
and B subunits, while the platelet zymogen has A subunits
only. Both zymogens form the same enzyme. Erythrocytes, in
contrast, contain a tissue transglutaminase that is distinct from
Factor XIII. In this study other bone marrow-derived cells
were examined for transglutaminase activity. Criteria that were
used to differentiate Factor XIII proteins from erythrocyte
transglutaminase included: (a) immunochemical and immuno-
histochemical identification with monospecific polyclonal and
monoclonal antibodies to Factor XIII proteins, (b) requirement
for thrombin cleavage to express activity, (c) pattern of fibrin
cross-linking catalyzed by the enzyme, and (d) different elec-
trophoretic mobilities in nondenaturing gel systems. By these
criteria human peripheral blood monocytes, peritoneal macro-
phages, and monocytes maintained in culture contain an intra-
cellular protransglutaminase that is the same as platelet Factor
XIII. The monocyte-macrophage protein is thrombin-sensitive,
and under appropriate conditions there is no enzyme expression
without activation of the zymogen. Both the monocyte-macro-
phage zymogen and enzyme have the same electrophoretic
mobilities as platelet Factor XIII zymogen and enzyme. Anti-
body to A protein reacts with the monocyte-macrophage protein.
B protein is not associated with this intracellular zymogen. By
immunoperoxidase staining monocyte-macrophage protein
seems to be localized in the cytoplasm, similar to the known
cytoplasmic distribution of platelet and megakaryocyte Factor
XIII. These procedures were also used to study populations of
human granulocytes and lymphocytes, and protransglutaminase
activity was not observed in these cells.
Introduction
Transglutaminases constitute a class of widely dispersed, Ca2+-
dependent enzymes that catalyze an acyl transfer reaction
between the y-carboxamide group ofa peptide-bound glutamine
residue and various primary amines. Several distinct types of
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transglutaminases have been identified, of which the most well
characterized are tissue transglutaminase and Factor XIIIa. A
tissue transglutaminase, which may be present in many cell
types, is usually isolated from liver or erythrocytes (1). It is a
monomeric protein (relative molecular weight [Mn' - 75,000-
80,000) which has only been detected as an active enzyme; no
zymogen has been found (2-4). Factor XIIIa, the blood
coagulation enzyme that was first found to catalyze the covalent
stabilization of fibrin, exists in two zymogenic forms. Extra-
cellular or plasma Factor XIII is a noncovalently associated
tetramer (MW- 320,000), consisting of two A and two B
subunits; intracellular Factor XIII is a dimer (Mr - 150,000)
of A subunits. The A chains in both zymogens are identical
(Mr - 75,000) (5). With activation, both zymogens give rise
to the same enzymatic activity. Intracellular Factor XIII has
been identified in platelets, megakaryocytes, placenta, and
uterus (6, 7).
Transglutaminase activity can be monitored by the covalent
incorporation of a suitable primary amine, usually a lysine
analogue such as dansylcadaverine or putrescine, into a peptide-
bound acceptor glutamine residue (8, 9). Factor XIIIa activity
can be differentiated from tissue transglutaminase by the
requirement for activation of the Factor XIII zymogen to
expose the active center cysteine. This is usually achieved by
thrombin cleavage of the A protein in the presence of calcium
ions (10). Other in vitro mechanisms for zymogen activation
include high concentration of calcium alone or calcium plus
thiocyanate (1 1-13). Tissue transglutaminase is immunochem-
ically distinct from platelet and plasma Factor XIII. The tissue
protein and the Factor XIII proteins also have different elec-
trophoretic mobilities in nondenaturing gel systems (14, 15).
Using an assay based on the incorporation of ['4C]putrescine
into NN'-dimethylcasein, Novogrodsky et al. (16) identified
transglutaminase activity in human peripheral blood lympho-
cytes and macrophages and also found that enzyme activity in
lymphocytes, but not in macrophages, was enhanced by prior
incubation of the cells with high concentrations of concanavalin
A and phytohemagglutinin. Schroff et al. (17) used fluorescent
staining of cells with dansylcadaverine and incorporation of
['4C]putrescine into a-casein by cell homogenates to detect
transglutaminase activity in murine macrophages. In this study
monocytes were negative and so also were lymphocytes, with
or without concanavalin A stimulation. Transglutaminase ac-
tivity has also been detected in murine leukemia Ml cells
during the course of differentiation into mature, macrophage-
like Ml+ cells (18). Murtaugh et al. (19) observed high levels
of transglutaminase in mouse peritoneal macrophages that had
been cultured in mouse plasma or serum. This activity was
not enhanced by lipopolysaccharide activation of the macro-
phages. However, Murtaugh et al. (20) also found that trans-
glutaminase activity of human monocytes in culture increased
1. Abbreviations used in this paper: Mn, relative molecular weight.
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with lipopolysaccharide stimulation. In these studies it was
concluded that the enzyme detected was tissue transglutaminase.
We have used monoclonal and polyclonal antibodies to
Factor XIHI proteins, activity measurements, and electrophoretic
mobility in a nondenaturing system, to characterize transglu-
taminase activity in human monocytes and macrophages.
These studies show that monocytes and macrophages contain
a zymogen identical to intracellular or platelet Factor XIII.
This zymogen is immunochemically identical to the A protein
of Factor XIII; it also has the same activation requirement
and electrophoretic mobility. We have not observed transglu-
taminase activity in granulocytes or lymphocytes.
Methods
Cell preparations. Macrophages were isolated from peritoneal fluid
obtained from healthy women undergoing laparoscopic bilateral tubal
ligation or from patients with endometriosis. Peritoneal fluid was
aspirated under direct visual control through a catheter (Silastic Medical
Products, Dow Corning Corp., Midland, MI); it was placed in tubes
containing heparin and was centrifuged at 300 g for 5 min. If the fluid
contained an excess of erythrocytes, it was underlayered with Ficoll-
Hypaque (LSM Litton Bionetics, Kensington, MD) and centrifuged at
400 g for 10 min. The cells were washed three times in cold RPMI
1640 medium. With this procedure macrophages composed 85-99%
of the nucleated cells.
Mononuclear cells from healthy blood donors were isolated on
Ficoll-Hypaque gradients (21). Minimal platelet contamination of the
mononuclear cell fraction (one platelet per 100 mononuclear cells)
was obtained by centrifuging the cells through human serum at room
temperature at 300 g for 10 min. By light microscopy no platelets were
seen adhering to the monocytes. Monocytes were separated from
lymphocytes by adherence to Petri dishes coated with human serum
for 45 min at 37°C and in 5% CO2. Nonadherent lymphocytes were
then removed by vigorous washing. The 98-99% pure monocyte
population was detached from the plates by exposure to ice-cold
Versene 1:5,000 (Gibco Laboratories, Grand Island, NY) for 5 min.
Granulocytes were obtained by suspending the pellet from the
Ficoll-Hypaque gradient with dextran (22).
Monocytes and macrophages were identified on cytocentrifuge
preparations by morphology, nonspecific esterase stain (23), and by
phagocytosis of opsonized zymosan particles. Monocyte cultures were
established from mononuclear cells adjusted to 4 X 10'/ml. Cells were
plated in 16-mm wells, and after 45 min nonadherent cells were
removed by vigorous washing. Monocytes were cultured in Eagle's
minimal essential medium-alpha with 5% AB' serum and antibiotics
at 37°C and 5% CO2. These culture conditions led to maturation of
monocytes to macrophages, as indicated by increased cell size, spreading,
phagocytic activity, and lysosomal enzyme content. Monocytes-mac-
rophages were harvested at various times in culture by first detaching
them with ice-cold Versene 1:5,000. Culture medium was concentrated
with a Diaflo PM30 ultrafilter (Amicon Corp., Danvers, MA), with a
membrane retentivity exceeding a molecular weight of 30,000.
Erythrocytes were isolated from citrated blood and washed with
isotonic buffer. Packed cells were stored at -80°C and thawed quickly
at 37°C immediately before use.
Cell extracts. Mononuclear cells were suspended at -10'/ml in
RPMI 1640 and were centrifuged at 1,100 g for 10 min at 4°C. Cell
pellets were resuspended in 0.01 M Tris, 0.1 M NaCl, 0.001 M EDTA,
pH 7.5. Two procedures were used to lyse the cells. In some experiments
0.5% Triton X-100 was incorporated into the buffer, and the cells were
incubated for 45 min at 4°C. In other experiments the cells were
suspended in buffer without Triton X-100 and disrupted in an Omni-
mixer (Sorvall, Newtown, CT) with five 30-s bursts at 4°C. Both
procedures gave the same results. Lysed cells were centrifuged at
10,000 g for 20 min. Throughout the procedure the cells and cell
lysates were kept at 4VC; and after the final centrifugation, the
supernatant was removed and assayed immediately for Factor XIII
activity.
Erythrocytes were disrupted in a tissue homogenizer in buffer
containing 2 mM EDTA and were otherwise treated similarly to the
mononuclear cells.
Protein concentration of cell extracts was determined with the
protein assay from Bio-Rad Laboratories, Richmond, CA, with bovine
albumin as the standard. Samples containing Triton X-100 were
corrected for the presence of detergent.
Activity measurement. Factor XIII activity was quantitated by
incorporating monodansylcadaverine (Sigma Chemical Co., St. Louis,
MO) into casein (8). The complete assay system included preincubation
of test material with thrombin and CaCl2 to activate the zymogen.
Test samples were also assayed without thrombin and CaCl2 activation
and with thrombin alone and CaCI2 alone. In all cases CaCl2 was
present in the incorporation phase. Pooled normal, platelet-poor plasma
and preparations of purified plasma Factor XIII (24) and platelet
Factor XIII (25) were used as controls for all studies. This assay can
detect - 10-15 ng ofA protein activity.
Assessment of electrophoretic mobility, based on activity detection,
was made by activity staining of the gel, after electrophoresis under
nondenaturing conditions (14). Agarose gel electrophoresis was per-
formed at 10'C at 18-20 V/cm in 1-mm thick gels containing 0.8%
agarose (Seakem, Springfield, NJ), on GelBond NF supports. Samples
were subjected to electrophoresis in 0.1 M Barbital I (Bio-Rad Labo-
ratories), pH 8.6, containing 2 mM EDTA. Factor XIII activity was
visualized by staining the electropherograms at 370C for 90 min with
a solution containing 10 IU/ml bovine thrombin (Parke-Davis), 35
mM CaC12, 2 mM dithiothreitol, 0.7 mM monodansylthiacadaverine
(Larodan Fine Chemicals, Malmo, Sweden), and 1.0% casein Ham-
marsten (ICN K & K Laboratories, Inc., Plainview, NY) in 50 mM
Tris-HCI, pH 7.5. In some experiments thrombin or CaCl2 was omitted
from the staining solution. Purified plasma and platelet Factor XIII
and erythrocyte transglutaminase were used as electrophoretic mobility
markers for the various types of transglutaminases. After incubation
in the staining solution, gels were immersed in 10% trichloroacetic
acid for 20 min, washed repeatedly in 10% acetic acid, and then
neutralized in 50 mM Tris-HCl, pH 7.5. Fluorescent bands were
readily visualized in ultraviolet light, and they were photographed
through a Wratten No. 15 filter. This procedure can detect <0.9 nM
Factor XIII activity.
Immunochemical characterization. Both monoclonal and polyclonal
antibodies to Factor XIII proteins were used. Monoclonal antibodies
were prepared by immunizing with purified preparations of A and B
proteins. Positive clones were subcloned in soft agar two or three times
(26). Monoclonal antibodies were characterized with respect to im-
munoglobulin class, ability to bind the various molecular forms of
Factor XIII proteins, and ability to inhibit Factor XIII activation or
activity. Monoclonal antibodies to A protein and to B protein were
used for immunoblotting (27, 28), after electrophoresis of samples in
6% sodium dodecyl sulfate (SDS) polyacrylamide gels (29).
Monospecific rabbit antisera were used to detect Factor XIII in all
extracts by crossed immunoelectrophoresis (30). It had previously been
determined that anti-A reacted only with A and not B, and anti-B
reacted only with B and not A (31, 32). These antisera did not react
with tissue transglutaminase.
Both monoclonal and polyclonal antibodies were used for immu-
nohistochemical examination of cells by the immunoperoxidase method
(33, 34), using the Vectastain ABC Reagent (Vector Laboratories, Inc.,
Burlingame, CA). Cytocentrifuge preparations were fixed in methanol/
acetone (50:50) or calcium acetate formalin before staining.
Fibrin cross-linking. To assess the substrate specificity of monocyte-
macrophage transglutaminase, fibrin gels were cross-linked with activated
macrophage transglutaminase, and the cross-linking pattern was deter-
mined by reduced SDS gel electrophoresis (35). In some experiments
fibrinogen pretreated with p-chloromercuribenzoate to inactivate all
traces of contaminating Factor XIII (36) was used as substrate. In
other experiments plasma from a patient with homozygous Factor
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XIII deficiency (<1% Factor XIII) was used. With both test systems, a
trace amount of 125I-fibrinogen (37) was added. After electrophoresis,
autoradiograms were prepared.
Results
Transglutaminase activity in blood cells was initially charac-
terized by electrophoretic mobility in nondenaturing, nonre-
ducing buffer, with in situ demonstration ofenzymatic activity.
Fig. 1 shows the presence of transglutaminase activity in cell
lysates prepared from peritoneal fluid macrophages (lane 1),
peripheral blood monocytes (lanes 4, 5), platelets (lane 6), and
erythrocytes (lane 8), with plasma Factor XIII (lane 7), as
control. The known mobility difference in this gel system
between plasma and platelet Factor XIII versus erythrocyte
(tissue) transglutaminase is apparent. It can be seen that the
activity observed in the monocyte-macrophage lysates migrated
with platelet and plasma Factor XIII. Granulocytes and lym-
phocytes, obtained from normal donors, were found to be
negative (lanes 2, 3). For these experiments any remaining
contaminating monocytes were separated out by allowing the
cells to ingest iron particles for 1 h at 370C and then removing
them with a magnet. In some experiments lymphocytes were
very faintly positive, which may have been due to failure to
remove all contaminating monocytes from the lymphocyte
preparation.
The requirement for activation of macrophage protransglu-
taminase is demonstrated in Fig. 2 with cell extracts of
peritoneal macrophages from three patients. Electrophoresis of
cell extracts and plasma was done without preactivation, and
then half of the gel was stained for transglutaminase with
thrombin activation and the other half without thrombin. As
would be expected, Factor XIII activity was observed in the
plasma sample that was thrombin activated (lane 1) but not
in the unactivated sample (lane 8). Identical results were
obtained with the three macrophage samples. When macrophage
samples were rapidly and carefully processed from freshly
obtained cells, transglutaminase activity was consistently not
observed by activity staining of electropherograms in the
absence of thrombin at the CaCl2 concentration used. The
converse was also true; no transglutaminase activity was ob-
served in plasma or in macrophage extracts when the gels
were stained with a solution containing thrombin but no
CaCl2. Expression of activity in macrophages, as in plasma,
Figure 1. Electrophoresis
- and activity staining for
the detection of transglu-
taminase activity in cell
lysates of human perito-
neal macrophages and pe-
ripheral blood cells. Aga-
rose electrophoresis in
2 3 4 5 6 7 8 barbital buffer was per-formed at 10-12 V/cm at
10°C for '90 min on
samples of freshly prepared extracts. Staining solution for visualiza-
tion of enzymatic activity contained thrombin, CaCI2, monodansyl-
thiacadaverine, dithiothreitol, and casein. Cell extracts are from: 1,
peritoneal fluid macrophages (2 X 106 cells/100 sd); 2, granulocytes
(2 X 106/100 Al); 3, lymphocytes (1.7 X 106/100 Ml); 4 and 5,
monocytes (2 X 106/100 ul); 6, platelets (2 X 106/100 gl); 7, plasma
control; 8, erythrocytes (2 X 106/100 gl).
1 2 3 4 5 6 7 8
Figure 2. Demonstration of thrombin activation of macrophage
transglutaminase. Samples were examined by agarose electrophoresis
in barbital buffer under nondenaturing, nonreducing conditions. Af-
ter electrophoresis the plate was divided in half for activity staining.
Lanes 1-4 were developed with staining solution containing throm-
bin (as in Fig. 1), and lanes 5-8 were stained with the same solution
except that thrombin was omitted. Samples: plasma Factor XIII
(control) in lanes I and 8 and macrophage cell lysates from three
patients (lanes 2-4 and 5-7).
required complete activation, in this case, with thrombin and
CaC12. However, it should be noted that transglutaminase
activity could be readily generated during storage of cells and
cell lysates, and it was only fresh extracts that were consistently
negative. We have also observed similar activation of platelet
Factor XIII in stored, lysed platelets and in placental extracts.
Direct experiments were also performed to quantitate the
transglutaminase activity in monocyte and macrophage lysates
by means of the dansylcadaverine incorporation assay. In this
assay, also, activity was not observed in fresh cell extracts
unless the samples were treated with thrombin. With the
complete activation system, the transglutaminase activity of
three monocyte preparations was measured in the soluble
fraction from 106 cells. The values were 0.10, 0.18, and 0.25
,umol dansylcadaverine incorporation per 20 min incorporation
time. With four peritoneal fluid macrophage preparations, the
values were 0.15, 0.23, 0.38, and 1.41 gmol/106 cells per 20
min. Granulocyte and lymphocyte cell lysates were also assayed
in the dansylcadaverine incorporation assay and were found
to be negative.
Further experiments were performed to characterize mono-
cyte-macrophage protransglutaminase immunochemically. Fig.
3 shows an immunoblot of purified platelet Factor XIII (lanes
I and 2) and macrophage cell lysate (lanes 3 and 4), which
was developed with monoclonal antibody to A protein. Lanes
1 and 3 contain untreated samples and lanes 2 and 4 contain
material preincubated with thrombin. It can be seen that the
monoclonal antibody recognizes a protein in the macrophage
cell lysate (lane 3) with a mobility identical to platelet A
protein (lane 1). Furthermore, after partial activation with
thrombin, both the A and cleaved A bands are visible in the
macrophage preparation (lane 4). In similar experiments in
which the transblot was stained with monoclonal anti-B, no
bands were visualized, indicating the absence of B protein
both in platelet Factor XIII and in the macrophage cell lysate.
Crossed immunoelectrophoresis was used to characterize
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Figure 3. Western blot
analysis of macrophage cell
lysate. After electrophoresis
in nonreducing SDS gels,
samples were transferred to
nitrocellulose and immu-
noblotted with monoclonal
antibody to Factor XIII A
subunit, and an autoradio-
gram was developed. Sam-
ples are: I and 2, purified
intracellular Factor XIII; 3
_ - _ and 4, macrophage cell
RI., _ lysate prepared from
3.9 x 10 cells. Samples 2
V and 4 were preincubated
A with thrombin before elec-2 3 4I trophoresis.
monocyte-macrophage lysates further. On crossed immuno-
electrophoresis with polyclonal anti-A, extracts from cultured
monocytes and from peritoneal fluid macrophages formed
precipitin arcs, which were the same as that formed with
plasma or platelet Factor XIII. Analysis of B protein was
carried out by electrophoresis of duplicate samples in agarose
containing anti-B serum and then developing the precipitin
arc in one sample with activity stain for A and the other
sample with protein stain. If the test material contains plasma
Factor XIII (A2B2), activity stain will visualize a precipitin arc
that is coincident with the B protein arc. If the sample contains
A but not B protein the activity stain will visualize a diffuse
spot which is not related to any precipitin arc. Fig. 4 shows
the results of this experiment. When purified A2B2 was tested,
activity staining revealed a fluorescent arc which was in the
same position as the B protein arc, indicating coelectrophoresis
of the A and B proteins in the plasma zymogen complex
(sample 3). When excess A protein was added to A2B2, both
a fluorescent arc and a diffuse fluorescent spot above it were
observed, indicating the presence of uncomplexed A protein
(sample 2). When macrophage extract was tested under the
same conditions, only a diffuse activity spot was observed,
which was in the same position as the spot for free A protein
(sample 1). Protein stain of the macrophage extract for B did
not visualize any arc. These results also indicate that macro-
phage extracts contain a protein with potential transglutaminase
1 2 . 3
Figure 4. Crossed immunoelectrophoresis with antiserum to Factor
XIII B subunit and activity staining to visualize A subunit, as de-
scribed in Methods. Samples are: 1, macrophage extract; 2, purified
plasma Factor XIII with purified platelet Factor XIII added; 3,
purified plasma Factor XIII.
activity which is immunochemically identical to the A protein
of Factor XIII. There is no evidence for B protein in macro-
phages.
Immunoperoxidase staining was used to localize A protein
in monocytes and macrophages. Fig. 5 shows the appearance
of cells in culture for 6 d, which were stained with monoclonal
antibody to A protein. Positive staining was seen throughout
the cytoplasm in a diffuse, lace-like pattern. There was no
specific staining of the plasma membrane, nucleus, or other
subcellular organelles. Staining was not observed with an
irrelevant monoclonal antibody. Identical results were obtained
with polyclonal anti-A, which also showed diffuse, cytoplasmic
staining. Anti-A serum, blocked with purified A protein, was
negative. Cytocentrifuge preparations of peripheral blood
mononuclear cell fraction were also stained with monoclonal
antibody to A protein. Platelets and monocytes were clearly
positive, while lymphocytes were negative.
Factor XIII-deficient plasma, to which a trace amount of
'I-fibrinogen was added, was clotted with thrombin and
CaCl2, with and without an added source of Factor XIII. The
clot was then washed and solubilized in urea-SDS-dithiothreitol
buffer, and the covalent cross-linking pattern was assessed by
gel electrophoresis and autoradiography (Fig. 6). The control
sample, with only buffer added, showed the typical reduced
SDS gel pattern of noncross-linked fibrin, that is, y, fl, and a
chains, with no y-dimer or a-polymer. Samples to which
purified plasma Factor XIII or monocyte/macrophage cell
lysate was added contained cross-linked y-dimer and a-polymer,
as well as some uncross-linked a-chain and free 3-chain. The
same results were obtained when Factor XIII-free fibrinogen
was used as the substrate.
Transglutaminase activity was also measured in monocytes
in culture. Cell extracts prepared from 106 fresh monocytes,
when assayed after thrombin and CaCl2 activation, catalyzed
the incorporation of 1.83±0.60 nmol dansylcadaverine per ,.g
protein. For day 3-4 monocytes and day 5-6 monocytes in
culture the comparable values were 0.96±0.08 and 1.77±0.32
nmol dansylcadaverine incorporation per Ag protein. These
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Figure 5. Immunoperoxidase staining of monocytes which had been
cultured for 6 d as described in Methods. After washing and fixation
the cells were reacted with monoclonal antibody to the A protein.
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Figure 6. Pattern of fibrin
cross-linking catalyzed by mac-
rophage enzyme. Factor XIII-
deficient plasma, to which a
trace of 1I-fibrinogen was
added, was clotted with throm-
bin and CaC12 and either puri-
fied Factor XIII or macrophage
cell lysate. Clots were washed,
subjected to reduced SDS elec-
trophoresis, and an autoradio-
gram was prepared. Lane 1,
control (no Factor XIII or
other source of transglutamin-
ase) showing pattern of non-
cross-linked fibrin; lane 2,
cross-linked fibrin formed with
added Factor XIII; lane 3,
2 3< cross-linked fibrin formed with
macrophage lysate.
the 7-d culture period, it remained constant with respect to
total protein. From our measurements of activity and protein,
both with purified preparations and also in plasma, we can
calculate the specific activity of Factor XIII to be 1.5-2.0 ,umol
of dansylcadaverine incorporation per 30 min per Mig of A
protein. On this basis A protein comprises 1 ng per ug of
total cytoplasmic protein in the cultured monocytes. 24-h and
72-h conditioned media were also tested and were found to
be no different from fresh medium. The small amount of
activity in the medium was due to the presence of activated
Factor XIII in the serum added to the medium. Thus, under
the culture conditions used, protransglutaminase was not se-
creted into the culture medium.
Discussion
The results presented here indicate that human monocytes
and macrophages contain a protransglutaminase that has the
same characteristics as intracellular or platelet Factor XIII.
The monocyte-macrophage protein is thrombin-sensitive (Fig.
2), and in most experiments no transglutaminase activity could
be observed without pretreatment with thrombin. The zymogen
is immunochemically identical to the A chain of Factor XIII,
as shown with both monoclonal and polyclonal antibodies to
A; and it does not contain the B chain of plasma Factor XIII
(Figs. 3-5). Known intracellular forms of Factor XIII, found
in platelets, megakaryocytes, and placenta, contain A subunits
only. The precursor and active enzyme forms of the monocyte-
macrophage protein have electrophoretic mobilities similar to
Factor XIII (Fig. 1). Monocyte-macrophage protein is localized
in the cell cytoplasm. When monocytes in culture were observed
by immunoperoxidase staining with antibody to A chain, the
cytoplasm was positive but there was no staining associated
with the plasma membrane or subcellular organelles. By im-
munofluorescence platelet and megakaryocyte Factor XIII
were previously found to be cytoplasmic constituents (6).
The fibrin cross-linking reactions catalyzed by monocyte-
macrophage transglutaminase are the same as those obtained
with Factor XIIIa. When fibrinogen is clotted with thrombin
and CaCl2 in the presence of either plasma or platelet Factor
XIII, the resulting fibrin exhibits a typical covalent cross-
linking pattern, composed of free ,8-chains, y-chain dimer, and
high molecular weight a-chain polymer, on SDS gels (38).
Tissue transglutaminase will also cross-link fibrin, but the
cross-linking pattern shows high molecular weight polymers of
a-chains and y-chains and no y-chain dimer formation (7).
When Factor XIII-deficient plasma or Factor XIII-free fibrin-
ogen was clotted with the macrophage soluble fraction, and
the clot was solubilized and examined by reduced SDS gel
electrophoresis, the fibrin cross-linking pattern showed 'y-
dimer and a-polymer formation (Fig. 6). y-dimer formation
differentiates Factor XIIIa activity from tissue transglutaminase,
since y-dimers are not observed with the tissue enzyme (7).
The possibility that monocytes-macrophages absorbed A
chain from plasma or serum is unlikely. Plasma A chain forms
a tight noncovalent complex with B chain; and there is no
evidence for free, uncomplexed A chain in plasma, either in
the precursor or active enzyme forms. We have also not been
able to find free B chain in plasma (32). It seems improbable,
therefore, that monocytes selectively absorb A chain, leaving
B chain behind in plasma. Serum contains a small amount of
A chain, which is all in the active enzyme form (32). Hence,
this is not the source of A chain for the monocytes in culture.
In addition, cells cultured in serum-free medium also contain
protransglutaminase.
Additional support for the identification of A protein in
monocytes is also provided by our recent studies with the
human monocyte-macrophage cell line, U937. These cells
stain with antibodies to A protein but not B protein, and the
cell cytosol contains a protransglutaminase which is thrombin
sensitive. When the cells are maintained in culture for 48 h in
serum-free medium, no protransglutaminase activity can be
detected in the cytosol without thrombin activation (39). The
results presented thus indicate that human monocytes and
macrophages contain a cytoplasmic protein with potential
transglutaminase activity, which is identical to the A protein
of plasma and platelet Factor XIII. This conclusion is based
on immunochemical identification, activation requirements,
electrophoretic mobility, and fibrin cross-linking pattern of the
monocyte-macrophage protein.
It should be noted that other investigators ( 16-20), working
with both murine and human monocytes and macrophages,
have identified transglutaminase activity in these cells with
apparently different characteristics from those described here
and have identified the enzyme as tissue transglutaminase. It
is not entirely clear how the present and previous studies
should be reconciled. By definition tissue transglutaminases
are a group of related intracellular enzymes with molecular
weight of -75,000-80,000 which can be differentiated from
the Factor XIIIa type of transglutaminases on the basis of
immunochemical characterization, requirement for zymogen
activation, electrophoretic mobility in nondenaturing systems,
and pattern of covalent cross-linking of a fibrin substrate (1-
3, 7). Importantly, there is thought to be no immunochemical
cross-reactivity between the tissue-type and Factor XIII-type
proteins (7). However, differentiation may be difficult.
In other studies, for example, transglutaminase activity was
detected in assay systems that did not employ thrombin,






implying that the active enzyme was present in the cells.
However, our experience with platelet and placental Factor
XIII, as well as monocyte and macrophage extracts, indicates
that zymogen activation may occur readily in cell lysates.
Factor XIII in platelet or placental extracts will readily undergo
conversion to enzyme if it is not rapidly and carefully separated
from the cytosol. There is evidence that cathepsin C or
catheptic carboxypeptidase can activate intracellular Factor
XIII, and this activation is facilitated by CaCl2 and reducing
agents (Lynch, G., and S. Pfueller, unpublished observations).
This may also be a pathway for activation of monocyte-
macrophage Factor XIII. Another possible mechanism might
involve CaCl2 alone or in conjunction with an intracellular
calcium binding protein. To obtain Factor XIII in the zymo-
genic form from monocytes and macrophages, as well as from
platelets and placenta, it is necessary to disrupt the cells in the
presence of a calcium chelator and in the absence of reducing
agents. Consequently, it is not surprising that an active trans-
glutaminase was observed in other studies.
It is not possible now to ascertain whether monocytes and
macrophages contain one or more than one cytoplasmic
transglutaminase. Our results are compatible with the conclu-
sion that these cells contain Factor XIII A chain, which can
be activated readily by thrombin-independent pathway(s). In
our most carefully prepared samples, this zymogen seems to
account for all of the intracellular transglutaminase activity
and represents ~-0.1% of the total cellular protein. This is the
same concentration that Murtaugh et al. (20) observed for
tissue transglutaminase in human monocytes in culture. It is
possible that under different conditions different transgluta-
minase activities may be expressed by the cells. Other work
has also suggested that there may be more than one intracellular
transglutaminase (1, 40), and there is immunochemical evidence
for the presence of tissue transglutaminase in macrophages
(19). However, the antibody to tissue transglutaminase used
by Murtaugh et al. (20) also detected transglutaminase in
human platelet extracts. Platelet transglutaminase is chemically
and immunochemically identical to the A subunit of plasma
Factor XIII (5-7).
In this study transglutaminase activity was not observed in
granulocytes. By activity staining lymphocytes were also essen-
tially negative. Very low activity was occasionally observed,
which may have been due to the presence of some monocytes
in the lymphocyte preparations. We have not been able to
demonstrate the presence of A protein in unstimulated lym-
phocytes.
A specific function for monocyte-macrophage transgluta-
minase has not yet been determined. One possibility that has
received attention involves receptor-mediated phagocytosis (41).
a2-macroglobulin is known to be a substrate for plasma Factor
XIIIa (42, 43), and macrophages bind a2-macroglobulin-pro-
tease complexes (44). Evidence has been presented that ligand-
receptor binding and internalization of a2-macroglobulin com-
plexes require transglutaminase activity and that inhibitors of
Factor XIII block both transglutaminase and endocytosis (45).
However, other investigators think that there are no direct
data to support a role for transglutaminases in this process
(46). Transglutaminase could be active in other macrophage
functions. It could, for example, be a source of readily acti-
vatable Factor XIII at inflammatory sites for the cross-linking
ofnumerous substrate proteins, including collagen, fibronectin,
and fibrinogen-fibrin. Monocytes-macrophages produce other
coagulation factors (47-49), and these cells can also function
in a manner similar to platelets to provide the membrane
surface on which the prothrombinase complex assembles for
the generation of thrombin (50). Macrophages can also release
fibrinolytic enzymes (51). It is therefore becoming clear that
macrophages may constitute an important cellular element in
the regulation of hemostasis. Several reactions involved in
fibrin formation and degradation require transglutaminase-
catalyzed covalent cross-linking. The availability of a macro-
phage source of Factor XIII in the local microenvironment of
clot formation requires further study to determine what role
it might have in these reactions.
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